Hexima Limited is pleased to announce today that it has completed enrolment for the dose escalation stage of its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “The HXP124 clinical trial is progressing well and it is very encouraging to complete enrolment for Part 1 of the study. Recruitment for Part 2 continues to progress well and we expect to have data from the trial before the end of the year.”

Read the full announcement here.